ALKALOID AD Skopje Sustainability Profile
ALKALOID AD Skopje, a leading pharmaceutical and chemical company, is headquartered in Skopje, North Macedonia (MK). Founded in 1936, the company has established itself as a key player in the industry, focusing on the production of a diverse range of products, including pharmaceuticals, herbal medicines, and active pharmaceutical ingredients (APIs). With a strong commitment to quality and innovation, ALKALOID AD has achieved significant milestones, expanding its operations across Europe and beyond. The company is renowned for its unique formulations and adherence to international standards, which have solidified its market position. Notable achievements include numerous awards for excellence in manufacturing and research, reflecting its dedication to advancing healthcare solutions.
DitchCarbon Score
How does ALKALOID AD Skopje's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ALKALOID AD Skopje's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ALKALOID AD Skopje's reported carbon emissions
In 2024, ALKALOID AD Skopje reported total carbon emissions of approximately 5,200,000 kg CO2e, comprising Scope 1 emissions of about 4,800,000 kg CO2e and Scope 2 emissions of around 4,100,000 kg CO2e. The Scope 1 emissions include mobile combustion (about 285,170 kg CO2e), fugitive emissions (about 73,050 kg CO2e), and stationary combustion (approximately 4,525,260 kg CO2e). Scope 2 emissions are primarily from purchased electricity, totalling about 4,087,420 kg CO2e. Additionally, Scope 3 emissions were reported at approximately 77,030 kg CO2e for business travel and 14,170 kg CO2e for employee commuting. In 2023, the company achieved significant reductions, with Scope 1 emissions decreasing by about 13% and Scope 2 emissions by approximately 62% compared to previous years. This commitment to reducing greenhouse gas emissions reflects ALKALOID AD Skopje's proactive approach to climate action. The company has not reported any SBTi targets or cascaded data from a parent organisation, indicating that its emissions data and reduction initiatives are independently managed. ALKALOID AD Skopje's climate commitments demonstrate a strong focus on sustainability and a clear strategy for reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 5,583,790 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,811,200 | 0,000,000 | 0,000,000 |
| Scope 3 | -313,880 | -0,000,000 | 00,000 |
How Carbon Intensive is ALKALOID AD Skopje's Industry?
How Carbon Intensive is ALKALOID AD Skopje's Location?
ALKALOID AD Skopje's Scope 3 Categories Breakdown
Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 1% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 84% of Scope 3 emissions.
Top Scope 3 Categories
ALKALOID AD Skopje's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ALKALOID AD Skopje has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
